title: Coming-of-Age of Antibodies in Cancer Therapeutics.
abstract: Antibody-based therapies have garnered considerable success in recent years. This is due to the availability of strategies to successfully engineer antibodies into humanized forms, better understanding of the biological processes involved in cancer development, the availability of novel recombinant antibody formats, better antibody selection platforms, and improved antibody conjugation methodologies. Such achievements have led to an explosion in the generation of antibodies and antibody-associated constructs for the treatment of cancer and other diseases. In this review, we critically assess recent trends in the development and applications of bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs) as cancer therapeutics. We also highlight recent US FDA approvals and clinical trials of antibody-based cancer therapies.
authors.affiliation: Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: vijiayyar@gmail.com.
authors.forename: B Vijayalakshmi
authors.initials: BV
authors.lastname: Ayyar
authors.affiliation: Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: Sushrut
authors.initials: S
authors.lastname: Arora
authors.affiliation: School of Biotechnology and Biomedical Diagnostics Institute, Dublin City University, Dublin 9, Ireland.
authors.forename: Richard
authors.initials: R
authors.lastname: O'Kennedy
mesh_terms: D000818:Animals; D000906:Antibodies / Q000008:administration & dosage* / Q000276:immunology; D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000276:immunology; D017277:Drug Approval; D015195:Drug Design; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D000906:Antibodies; D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; D018796:Immunoconjugates
keywords: antibody drug conjugates; antibody-based therapeutics; bispecific antibodies; cancer therapies; immune checkpoint inhibitors